ACE Report Cover
Periarticular and intravenous TXA comparable in blood loss and transfusion rates after TKA
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descarregar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descarregar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
ARTHROPLASTY
Periarticular and intravenous TXA comparable in blood loss and transfusion rates after TKA .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2016;4(20):5 BMC Musculoskelet Disord. 2016 Jul 26;17:313.
Autores contribuintes

P Pinsornsak S Rojanavijitkul S Chumchuen

60 patients scheduled for unilateral total knee arthroplasty were randomized to be administered either periarticular or intravenous tranexamic acid (TXA). The purpose of this study was to compare blood loss and adverse events throughout the first 48-hours post-surgery. The results from this trial demonstrated non-significant differences between groups for postoperative blood loss volume, hematocrit levels, hemoglobin concentration, the number of patients requiring transfusion, VAS pain scores, and thigh/leg circumference when evaluated at 24- or 48-hours postoperatively.


Detalhes do financiamento da publicação +
Financiamento:
Non-funded
Conflitos:
None disclosed

Risco de viés

6/10

Critérios de notificação

15/20

Índice de Fragilidade

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sim = 1

Incerto = 0,5

Não relevante = 0

Não = 0

A Avaliação dos Critérios de Relato avalia a transparência com que os autores relatam as caraterísticas metodológicas e do ensaio na publicação. A avaliação está dividida em cinco categorias que são apresentadas de seguida.

1/4

Randomization

2/4

Outcome Measurements

4/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

O Índice de Fragilidade é uma ferramenta que auxilia na interpretação de achados significativos, fornecendo uma medida de força para um resultado. O Índice de Fragilidade representa o número de eventos consecutivos que precisam de ser adicionados a um resultado dicotómico para que o resultado deixe de ser significativo. Um número pequeno representa um resultado mais fraco e um número grande representa um resultado mais forte.

Porque é que este estudo era necessário agora?

Intravenous tranexamic acid remains a popular mode of reducing postoperative blood loss after total knee arthroplasty. Despite its well-established anti-fibrinolytic efficacy, potential drawbacks such as thrombus formation and venous thromboembolism (VTE) still remain major concerns with the intravenous administration method. As a result, it has been suggested that other methods of application, such as topical administration or periarticular injection, may offer similar outcomes while reducing the risk of developing these complications.

Qual era a principal questão de investigação?

In patients undergoing unilateral total knee arthroplasty, did the periarticular injection of tranexamic acid (TXA) produce comparable results to conventional intravenous TXA in terms of postoperative blood loss, hemoglobin concentration, and the need for blood transfusion during the first 48 hours post-surgery?

Caraterísticas do estudo +
População:
60 patients (50-80 years) with knee osteoarthritis scheduled for total knee arthroplasty were included. Patients who reported daily aspirin use were asked to stop medication at least seven days prior to scheduled surgery. All patients received cemented, posterior-stabilized, fixed bearing prostheses without patella resurfacing. All procedures were performed via a medial parapatellar approach under tourniquet control.
Intervenção:
Periarticular group: patients received 750 mg periarticular tranexamic acid injection (15 cc of 250 mg/5mL Transamin, OLIC Thailand Ltd) to soft tissues surrounding the medial capsule, lateral capsule, and quadriceps muscle (n=30; 67.63+/-7.96, 25F/5M).
Comparação:
Intravenous group: patients received 750 mg intravenous tranexamic acid injection (15 cc of 250 mg/5mL solution) (n=30; 69.97+/-7.55, 23F/7M).
Resultados:
The primary outcomes included drain volume of postoperative blood loss, changes in serum hemoglobin, and requirement of blood transfusion. The requirement of blood transfusion was defined as a hemoglobin concentration less than 10 g/dL, or if patients demonstrated clinical symptoms of anemia (chest pain, heart failure, idiopathic tachycardia or hypotension). Secondary outcomes included knee diameter (swelling), local soft tissue complications, skin necrosis, venous thromboembolism (VTE), and VAS pain.
Métodos:
RCT: prospective, un-blinded, pilot study
Tempo:
Outcomes were assessed at 24 and 48 hours postoperatively.
Quais foram os resultados importantes?
  • The volume of blood present in Hemovac drain (postoperative blood loss) was not significantly different between periarticular and intravenous groups when compared at the 24-hour follow-up (300+/-128 vs. 334+/-124mL, respectively; p=0.279) or 24-48 hour follow-up (145+/-92 vs. 186+/-106mL, respectively; p=0.094).
  • Hematocrit levels for periarticular and intravenous groups were not significantly different when compared at 24 hours (29.7 vs 30.4; p=0.550) and 48 hours (31.0 vs. 31.8; p=0.352) postoperatively.
  • Hemoglobin concentrations were not significantly different between periarticular and intravenous groups when compared at 24 hours (9.60 vs 10.09; p=0.215) and 48 hours (10.16 vs 10.40; p=0.693) postoperatively.
  • The number of patients requiring blood transfusion was not significantly different between periarticular and intravenous groups (9 vs. 7, p=0.928).
  • Differences between periarticular and intravenous groups for thigh and leg circumference were not significant at 48 hours (p=0.398 and 0.052 respectively).
  • VAS pain scores measured at 24 hours (p=0.889) and 48 hours (p=0.724), Knee flexion at time of hospital discharge(p=0.087), and total length of hospital stay ( p=0.276) were comparable between periarticular and intravenous groups.
De que é que me devo lembrar mais?

For patients undergoing total knee arthroplasty, periarticular and intravenous administration of tranexamic acid (TXA) resulted in comparable postoperative blood loss volume, hematocrit levels, hemoglobin concentration, the number of patients requiring transfusion, VAS pain scores, and thigh/leg circumference throughout a 48-hour postoperative period.

Como é que isto afectará o tratamento dos meus doentes?

The results of this study demonstrated comparable effects of either periarticular or intravenous tranexamic acid on postoperative blood loss and clinical outcomes for patients undergoing unilateral TKA. Further investigation with dose-response analyses, a control group, and larger patient populations is recommended to both determine optimal dosing of either periarticular or intravenous TXA dosing and to determine if differences in safety outcomes exist.

AVISO LEGAL

O conteúdo desta página destina-se apenas a fins informativos e não pretende substituir o aconselhamento, diagnóstico ou tratamento médico profissional. Se necessitar de tratamento médico, procure sempre o conselho do seu médico ou dirija-se ao serviço de urgência mais próximo. As opiniões, crenças e pontos de vista expressos pelos indivíduos no conteúdo encontrado nesta página não reflectem as opiniões, crenças e pontos de vista da OrthoEvidence.

0 de 4 artigos mensais GRATUITOS desbloqueados
Atingiu o seu limite de 4 visualizações de artigos gratuitos este mês

Aceda à OrthoEvidence por apenas $1,99 por semana.

Mantenha-se ligado às últimas evidências. Cancele a qualquer altura.
  • Avaliações críticas dos mais recentes ensaios clínicos aleatórios de alto impacto e revisões sistemáticas em ortopedia
  • Acesso ao conteúdo do podcast OrthoEvidence, incluindo colaborações com o Journal of Bone and Joint Surgery, entrevistas com cirurgiões reconhecidos internacionalmente e discussões em mesa redonda sobre notícias e tópicos ortopédicos
  • Subscrição do The Pulse, um boletim informativo duas vezes por semana baseado em evidências, concebido para o ajudar a tomar melhores decisões clínicas
Upgrade
Close Dialog
Bem-vindo de volta!
Esqueceu-se da palavra-passe?
Comece hoje o seu teste GRATUITO!

A sua conta será afiliada a
e inclui acesso gratuito ao OrthoEvidence


OU
Esqueceu-se da palavra-passe?

OU
Verifique o seu e-mail

Se existir uma conta com o endereço de e-mail fornecido, ser-lhe-á enviado um e-mail de reposição da palavra-passe. Se não vir uma mensagem de correio eletrónico, verifique a sua pasta de spam ou de lixo eletrónico.

Para obter mais assistência, contacte a nossa equipa de apoio.

Inicie sessão para ativar esta funcionalidade

Para aceder a esta funcionalidade, tem de iniciar sessão numa conta OrthoEvidence ativa. Inicie a sessão ou crie uma conta de avaliação GRATUITA.

Traduzir o Relatório ACE

A OrthoEvidence utiliza um serviço de tradução de terceiros para tornar o conteúdo acessível em vários idiomas. Tenha em atenção que, embora sejam feitos todos os esforços para garantir a exatidão, as traduções podem nem sempre ser perfeitas.

Como citar isto ACE Report

OrthoEvidence. Periarticular and intravenous TXA comparable in blood loss and transfusion rates after TKA. OE Journal. 2016;4(20):5. Available from: https://myorthoevidence.com/AceReport/Show/periarticular-and-intravenous-txa-comparable-in-blood-loss-and-transfusion-rates-after-tka

Copie a citação
Inicie sessão para ativar esta funcionalidade

Para aceder a esta funcionalidade, tem de iniciar sessão numa conta OrthoEvidence ativa. Inicie a sessão ou crie uma conta de avaliação GRATUITA.

Funcionalidade de Membro Premium

Para aceder a esta funcionalidade, tem de ter sessão iniciada numa conta Premium da OrthoEvidence.

Partilhe isto ACE Report